161 related articles for article (PubMed ID: 23118528)
1. Multicomponent nanoparticles as nonviral vectors for the treatment of Fabry disease by gene therapy.
Ruiz de Garibay AP; Delgado D; Del Pozo-Rodríguez A; Solinís MÁ; Gascón AR
Drug Des Devel Ther; 2012; 6():303-10. PubMed ID: 23118528
[TBL] [Abstract][Full Text] [Related]
2. Solid Lipid Nanoparticles as Non-Viral Vectors for Gene Transfection in a Cell Model of Fabry Disease.
Ruiz de Garibay AP; Solinís MA; del Pozo-Rodríguez A; Apaolaza PS; Shen JS; Rodríguez-Gascón A
J Biomed Nanotechnol; 2015 Mar; 11(3):500-11. PubMed ID: 26307832
[TBL] [Abstract][Full Text] [Related]
3. Characterization of Fabry mice treated with recombinant adeno-associated virus 2/8-mediated gene transfer.
Choi JO; Lee MH; Park HY; Jung SC
J Biomed Sci; 2010 Apr; 17(1):26. PubMed ID: 20398385
[TBL] [Abstract][Full Text] [Related]
4. Correction of the nonlinear dose response improves the viability of adenoviral vectors for gene therapy of Fabry disease.
Ziegler RJ; Li C; Cherry M; Zhu Y; Hempel D; van Rooijen N; Ioannou YA; Desnick RJ; Goldberg MA; Yew NS; Cheng SH
Hum Gene Ther; 2002 May; 13(8):935-45. PubMed ID: 12031126
[TBL] [Abstract][Full Text] [Related]
5. Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors.
Przybylska M; Wu IH; Zhao H; Ziegler RJ; Tousignant JD; Desnick RJ; Scheule RK; Cheng SH; Yew NS
J Gene Med; 2004 Jan; 6(1):85-92. PubMed ID: 14716680
[TBL] [Abstract][Full Text] [Related]
6. Galactomannan-Decorated Lipidic Nanocarrier for Gene Supplementation Therapy in Fabry Disease.
Rodríguez-Castejón J; Gómez-Aguado I; Beraza-Millor M; Solinís MÁ; Del Pozo-Rodríguez A; Rodríguez-Gascón A
Nanomaterials (Basel); 2022 Jul; 12(14):. PubMed ID: 35889565
[TBL] [Abstract][Full Text] [Related]
7. Gene therapy for fabry disease: a review of the literature.
Ruiz de Garibay AP; Solinís MA; Rodríguez-Gascón A
BioDrugs; 2013 Jun; 27(3):237-46. PubMed ID: 23575647
[TBL] [Abstract][Full Text] [Related]
8. Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer.
Ziegler RJ; Yew NS; Li C; Cherry M; Berthelette P; Romanczuk H; Ioannou YA; Zeidner KM; Desnick RJ; Cheng SH
Hum Gene Ther; 1999 Jul; 10(10):1667-82. PubMed ID: 10428212
[TBL] [Abstract][Full Text] [Related]
9. Role of endocytic uptake in transfection efficiency of solid lipid nanoparticles-based nonviral vectors.
Ruiz de Garibay AP; Solinís Aspiazu MÁ; Rodríguez Gascón A; Ganjian H; Fuchs R
J Gene Med; 2013; 15(11-12):427-40. PubMed ID: 24339018
[TBL] [Abstract][Full Text] [Related]
10. Dextran and protamine-based solid lipid nanoparticles as potential vectors for the treatment of X-linked juvenile retinoschisis.
Delgado D; del Pozo-Rodríguez A; Solinís MÁ; Avilés-Triqueros M; Weber BH; Fernández E; Gascón AR
Hum Gene Ther; 2012 Apr; 23(4):345-55. PubMed ID: 22295905
[TBL] [Abstract][Full Text] [Related]
11. Development and characterization of an improved formulation of cholesteryl oleate-loaded cationic solid-lipid nanoparticles as an efficient non-viral gene delivery system.
Limeres MJ; Suñé-Pou M; Prieto-Sánchez S; Moreno-Castro C; Nusblat AD; Hernández-Munain C; Castro GR; Suñé C; Suñé-Negre JM; Cuestas ML
Colloids Surf B Biointerfaces; 2019 Dec; 184():110533. PubMed ID: 31593829
[TBL] [Abstract][Full Text] [Related]
12. Enzymatic and functional correction along with long-term enzyme secretion from transduced bone marrow hematopoietic stem/progenitor and stromal cells derived from patients with Fabry disease.
Takenaka T; Hendrickson CS; Tworek DM; Tudor M; Schiffmann R; Brady RO; Medin JA
Exp Hematol; 1999 Jul; 27(7):1149-59. PubMed ID: 10390190
[TBL] [Abstract][Full Text] [Related]
13. AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry mice.
Ziegler RJ; Lonning SM; Armentano D; Li C; Souza DW; Cherry M; Ford C; Barbon CM; Desnick RJ; Gao G; Wilson JM; Peluso R; Godwin S; Carter BJ; Gregory RJ; Wadsworth SC; Cheng SH
Mol Ther; 2004 Feb; 9(2):231-40. PubMed ID: 14759807
[TBL] [Abstract][Full Text] [Related]
14. Preselective gene therapy for Fabry disease.
Qin G; Takenaka T; Telsch K; Kelley L; Howard T; Levade T; Deans R; Howard BH; Malech HL; Brady RO; Medin JA
Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3428-33. PubMed ID: 11248095
[TBL] [Abstract][Full Text] [Related]
15. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice.
Jung SC; Han IP; Limaye A; Xu R; Gelderman MP; Zerfas P; Tirumalai K; Murray GJ; During MJ; Brady RO; Qasba P
Proc Natl Acad Sci U S A; 2001 Feb; 98(5):2676-81. PubMed ID: 11226298
[TBL] [Abstract][Full Text] [Related]
16. Retroviral coexpression of a multidrug resistance gene (MDR1) and human alpha-galactosidase A for gene therapy of Fabry disease.
Sugimoto Y; Aksentijevich I; Murray GJ; Brady RO; Pastan I; Gottesman MM
Hum Gene Ther; 1995 Jul; 6(7):905-15. PubMed ID: 7578409
[TBL] [Abstract][Full Text] [Related]
17. Enzymatic corrections for cells derived from Fabry disease patients by a recombinant adenovirus vector.
Ohsugi K; Kobayashi K; Itoh K; Sakuraba H; Sakuragawa N
J Hum Genet; 2000; 45(1):1-5. PubMed ID: 10697955
[TBL] [Abstract][Full Text] [Related]
18. Efficient correction of Fabry mice and patient cells mediated by lentiviral transduction of hematopoietic stem/progenitor cells.
Yoshimitsu M; Higuchi K; Ramsubir S; Nonaka T; Rasaiah VI; Siatskas C; Liang SB; Murray GJ; Brady RO; Medin JA
Gene Ther; 2007 Feb; 14(3):256-65. PubMed ID: 16929352
[TBL] [Abstract][Full Text] [Related]
19. Design flexibility influencing the in vitro behavior of cationic SLN as a nonviral gene vector.
Vighi E; Montanari M; Hanuskova M; Iannuccelli V; Coppi G; Leo E
Int J Pharm; 2013 Jan; 440(2):161-9. PubMed ID: 22982257
[TBL] [Abstract][Full Text] [Related]
20. α-Galactosidase delivery using 30Kc19-human serum albumin nanoparticles for effective treatment of Fabry disease.
Lee HJ; Park HH; Sohn Y; Ryu J; Park JH; Rhee WJ; Park TH
Appl Microbiol Biotechnol; 2016 Dec; 100(24):10395-10402. PubMed ID: 27353764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
